SEP 16·SEC EDGARLow
Chan Phillip P. purchased $23K of CTSO
Chan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.
StockNASDAQ · US · USDHealthcare · Medical Devices
$CTSO
Cytosorbents Corp
Price · $CTSOvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $CTSO in the last 7 days.
Insider · 30dAll trades →
- Buys
- $120K 7 txs
- Sells
- — 0 txs
Sobel Alan D.3× · $15K
10b5-1 share of filings0%
Top stories · $CTSOMore →
SEP 16·SEC EDGAR
Capponi Vincent purchased $13K of CTSO
Capponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.
SEP 16·SEC EDGAR
Sobel Alan D. purchased $15K of CTSO
Sobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.
CTSO sentiment & insider activity
Recent CTSO coverage spans insider activity, earnings and corporate actions.
In the last 30 days, CTSO insiders filed 7 SEC Form 4 transactions — 7 purchases ($120K) and no sales. The most active reporter was Sobel Alan D. with 3 filings.
What's driving CTSO
The purchase is small relative to the company's market cap and unlikely to move the stock.
Small insider purchase may signal confidence but size is negligible for price impact.
Small insider purchase; limited immediate price impact.
Small insider purchase may signal confidence but limited price impact.
The reverse split approval is a capital-structure catalyst that can affect liquidity, per-share pricing, and Nasdaq compliance optics.
AlphAI scores every news story that mentions CTSO with an AI model for sentiment and relevance, and aggregates insider trades from Cytosorbents Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CTSO
Score
Chan Phillip P. purchased $23K of CTSO
Chan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.
1 min readCapponi Vincent purchased $13K of CTSO
Capponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.
1 min readSobel Alan D. purchased $15K of CTSO
Sobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.
1 min readChan Phillip P. purchased $70K of CTSO
Chan Phillip P. (Chief Executive Officer) purchased 200,000 shares of Cytosorbents Corp (CTSO) at $0.35 on 2026-09-04.
1 min readCytosorbents Corp (CTSO): Submission of Matters to a Vote of Security Holders
Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders CytoSorbents Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on August 13, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1.
3 min read
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript
Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.
6 min read
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.6 million, unchanged year over year. Gross margin rose to 73%. Operating loss fell 27% to $2.6 million, and net loss was $4.4 million ($0.07/share). Adjusted net loss improved 22% to $2.8 million. Cash burn was $0.4 million. The company also discussed sales trends and FDA regulatory plans.
6 min readCytosorbents Corp (CTSO): Results of Operations and Financial Condition
Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme
6 min readMARIANI PETER J purchased $44K of CTSO
MARIANI PETER J (Chief Financial Officer) purchased 100,000 shares of Cytosorbents Corp (CTSO) at $0.44 on 2026-06-15.
1 min readChan Phillip P. purchased $105K of CTSO
Chan Phillip P. (Chief Executive Officer) purchased 261,469 shares of Cytosorbents Corp (CTSO) at an average of $0.40 ($0.40–$0.43, $0.10M total) across 2 trades over 2026-06-12 to 2026-06-15.
2 min read